Table 3.

Results of logistic model to distinguish patients with PCa from patients with BPH among AA patients for (A) 139 patients with PCa from 48 patients with BPH, (B) 139 patients with PCa from 25 patients with BPH with multiple negative biopsies, (C) 60 patients with Gleason Scores 7–10 PCa from 48 patients with BPH.

(A) African American Patients Comparing BPH vs. PCa
Model	Cutoff	AUC	Sensitivity	Specificity	PPV	NPV	OR (CI)	p-value	nBPH	nPCa
PSA	0.74	0.54	0.91	0.1	0.75	0.28	1.13 (0.297–3.62)	0.78	48	139
Age	0.58	0.74	0.91	0.4	0.81	0.59	6.27 (2.61–15.6)	7.7 × 10−6	48	139
FLNA	0.61	0.72	0.96	0.4	0.82	0.76	14.2 (4.94–47.5)	1.5 × 10−8	48	139
PSA + Age	0.56	0.74	0.91	0.4	0.81	0.59	6.27 (2.61–15.6)	7.7 × 10−6	48	139
FLNA + Age	0.57	0.79	0.91	0.5	0.84	0.65	9.53 (4.04–23.5)	1.3 × 10−8	48	139
FLNA + Age + Vol	0.6	0.82	0.91	0.58	0.86	0.68	13.3 (5.62–33.2)	3.2 × 10−11	48	139
(B) African American Patients Undergoing Multiple Biopsies
Model	Cutoff	AUC	Sensitivity	Specificity	PPV	NPV	OR (CI)	p-value	nBPH	nPCa
PSA	0.84	0.6	0.91	0.2	0.86	0.28	2.41 (0.606–8.24)	0.16	25	139
Age	0.7	0.82	0.91	0.52	0.91	0.5	10.3 (3.54–30.8)	3.1 × 10−6	25	139
FLNA	0.72	0.81	0.96	0.6	0.93	0.71	31.7 (9.33–125)	1.8 × 10−10	25	139
PSA + Age	0.69	0.82	0.91	0.48	0.91	0.48	8.76 (3–26.2)	1.7 × 10−5	25	139
FLNA + Age	0.7	0.89	0.91	0.6	0.93	0.54	14.1 (4.87–43.6)	7.7 × 10−8	25	139
FLNA + Age + Vol	0.72	0.89	0.91	0.68	0.94	0.57	19.9 (6.7–65)	1.2 × 10−9	25	139
(C) African American Patients Comparing BPH vs. PCa Gleason Score 7–10
Model	Cutoff	AUC	Sensitivity	Specificity	PPV	NPV	OR (CI)	p-value	nBPH	nPCa
PSA	0.55	0.5	0.92	0.17	0.58	0.62	2.18 (0.579–9.15)	0.24	48	60
Age	0.39	0.71	0.92	0.38	0.65	0.78	6.48 (2.06–24.6)	0.00031	48	60
FLNA	0.41	0.71	0.95	0.4	0.66	0.86	12.2 (3.2–69.3)	1.7 × 10−5	48	60
PSA + Age	0.35	0.72	0.92	0.38	0.65	0.78	6.48 (2.06–24.6)	0.00031	48	60
FLNA + Age	0.38	0.77	0.92	0.46	0.68	0.81	9.1 (2.94–34.3)	1.1 × 10−5	48	60
FLNA + Age + Vol	0.4	0.82	0.92	0.54	0.71	0.84	12.6 (4.1–47.7)	2.7 × 10−7	48	60